List view / Grid view
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
